Panc 10.05 (ATCC® CRL-2547)

Organism: Homo sapiens, human  /  Cell Type: epithelial  /  Tissue: pancreas  /  Disease: adenocarcinoma

Organism Homo sapiens, human
Tissue pancreas
Cell Type epithelial
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1
Disease adenocarcinoma
Age adult
Gender male
Ethnicity Caucasian
Storage Conditions liquid nitrogen vapor phase
Images CRL-2547 Micrograph
Derivation
Panc 10.05 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma.
The Panc 10.05 cell line was derived from the same patient as the PL45 cell line (ATCC CRL-2558).
Clinical Data
adult
male
Antigen Expression
MHC class I +; MHC class II -
Oncogene K-ras + RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
Genes Expressed
cytokeratins 7 and 18
Cellular Products
cytokeratins 7 and 18
Tumorigenic Yes
Effects
Yes, forms tumors in nude or SCID mice
Comments
Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine.
The cells have a reported plating efficiency of 40%.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
  • 10 Units/ml human recombinant insulin
  • fetal bovine serum to a final concentration of 15%

Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53% (w/v) EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C

Subculture Ratio: 1:2 to 1:4
Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.

Cryopreservation
Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage Temperature: Liquid nitrogen vapor phase
Culture Conditions
Temperature: 37°C
STR Profile
D5S818: 13
D13S317: 12
D7S820: 8,9
D16S539: 9,12
vWA: 16
THO1: 6,9.3
Amelogenin: X
TPOX: 11
CSF1PO: 12
Population Doubling Time 19.2 hrs
Name of Depositor EM Jaffee
Year of Origin 1992
References

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

Basic Documentation
Other Documentation
References

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602